Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ12121213-0,08
KB104210450,97
PKN86,0186,020,19
Msft503503,4-0,08
Nokia4,3834,3871,15
IBM289,3290,2-0,15
Mercedes-Benz Group AG52,8152,831,05
PFE25,4425,45-0,43
10.07.2025 11:15:00
Indexy online
AD Index online
select
AD Index online
 

  • 09.07.2025
Cerus Corp (NASDAQ Cons)
Závěr k 9.7.2025 Změna (%) Změna (USD) Objem obchodů (ks)
1,49 2,05 0,03 814 668
Premarket10.07.2025 10:55:47
Poslední obchod Nákup / Prodej Změna (%) Změna (USD) Objem obchodů (ks)
- 1,36 1,60 - - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 10.07.2025
Popis společnosti
Obecné informace
Název společnostiCerus Corp
TickerCERS
Kmenové akcie:Ordinary Shares
Kmenové akcie:Unit
RICCERS.O
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.12.2024 281
Akcie v oběhu k 17.04.2025 191 160 480
MěnaUSD
Kontaktní informace
Ulice1220 Concord Avenue
MěstoCONCORD
PSČ94520
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon19 252 886 000
Fax19252886001

Business Summary: Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Cerus Corp revenues increased 13% to $48.9M. Net loss decreased 20% to $7.7M. Revenues reflect Product revenue increase of 13% to $43.2M, Revenue increase of 12% to $5.6M. Lower net loss reflects Other income, net increase of 34% to $606K (income), Interest expense decrease of 6% to $2.1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.05 to -$0.04.
Odvětvová klasifikace
TRBC2012Medical Devices & Implants
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSSurgical and Medical Instrument Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Surgical & Medical Instrument Mfg
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Surgical and Medical Instrument Manufacturing
SICSurgical And Medical Instruments
SICSurgical And Medical Instruments
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace: 10.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorWilliam Greenman5818.04.2011
Chief Financial Officer, Vice President - FinanceKevin Green52
Chief Operating OfficerVivek Jayaraman4901.03.202029.08.2016
Chief Legal Office, General Counsel and SecretaryChrystal Jensen5303.12.2012
Chief Medical OfficerRichard Benjamin6413.07.201513.07.2015